RxDoctor Payments Data

Sarthak Khare, MD

Interventional Cardiology · Portsmouth, NHNPI 1366962177

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Edwards Lifesciences at 39.8% of the total. Reporting peaked in 2024 at $3,335 and has fallen 78.1% since, to $731 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NH, where the typical reported total is $5,309.

$5,309in general payments, 2019–2025

Across 73 payments — averaging $72.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Medtronic$1K
  • Abbott$575
  • Abiomed$346
  • Boston Scientific$277
  • Stryker$176
  • plus $387 from 5 others

What the payments were for

  • Travel & lodging$2,70651%
  • Food & beverage$2,40145%
  • Education$2024%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,309 in reported general payments places this provider in the 50th percentile of 26 interventional cardiology providers in New Hampshire.

See all interventional cardiology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$58,087
Medicare patients
527
Services billed
969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$18,354
EntrestoSacubitril/Valsartan13$13,571
Metoprolol Succinate17$133

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Portsmouth

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →